Marshall Wace’s Acrivon Therapeutics ACRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $216K | Sell |
181,187
-269,204
| -60% | -$320K | ﹤0.01% | 2299 |
|
|
2025
Q1 | $914K | Sell |
450,391
-147,403
| -25% | -$299K | ﹤0.01% | 1717 |
|
|
2024
Q4 | $3.6M | Sell |
597,794
-212,065
| -26% | -$1.28M | ﹤0.01% | 1117 |
|
|
2024
Q3 | $5.67M | Sell |
809,859
-139,007
| -15% | -$973K | 0.01% | 870 |
|
|
2024
Q2 | $5.5M | Buy |
948,866
+351,397
| +59% | +$2.04M | 0.01% | 868 |
|
|
2024
Q1 | $4.27M | Hold |
597,469
| – | – | 0.01% | 930 |
|
|
2023
Q4 | $2.94M | Hold |
597,469
| – | – | 0.01% | 902 |
|
|
2023
Q3 | $5.71M | Hold |
597,469
| – | – | 0.01% | 744 |
|
|
2023
Q2 | $7.74M | Hold |
597,469
| – | – | 0.02% | 734 |
|
|
2023
Q1 | $7.58M | Sell |
597,469
-625,783
| -51% | -$7.94M | 0.02% | 702 |
|
|
2022
Q4 | $14.1M | Buy |
+1,223,252
| New | +$14.1M | 0.03% | 545 |
|